市場調査レポート
商品コード
1378788
緑内障治療薬市場レポート:薬剤クラス別、適応症別、エンドユーザー別、地域別、2023-2028年Glaucoma Therapeutics Market Report by Drug Class, Indication, End User, and Region 2023-2028 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
緑内障治療薬市場レポート:薬剤クラス別、適応症別、エンドユーザー別、地域別、2023-2028年 |
出版日: 2023年11月02日
発行: IMARC
ページ情報: 英文 145 Pages
納期: 2~3営業日
|
世界の緑内障治療薬の市場規模は、2022年に74億米ドルに達しました。今後、IMARC Groupは、市場は2028年までに108億米ドルに達し、2022年から2028年の間に6.5%の成長率(CAGR)を示すと予測しています。世界の緑内障の有病率の増加、早期発見のための診断技術の継続的な進歩、眼科における遠隔医療の採用の増加、外科手術における多くの技術革新は、市場を推進している要因のいくつかを表しています。
緑内障は視神経の損傷をもたらす眼疾患群であり、視力喪失につながる可能性があります。通常、薬物療法、レーザー治療、または手術によって管理され、これらの介入は緑内障進行の重要な要因である眼圧(IOP)を下げることを目的としています。緑内障治療薬には通常、プロスタグランジン、β遮断薬、α作動薬などの薬剤が含まれ、眼液の産生を抑えたり、眼液の流出を改善したりすることを目的とした点眼薬が一般的です。海綿体形成術のようなレーザー治療も、眼液の排出を促進するためにレーザー光線を眼球の排出システムに集中させる方法です。トラベクレクトミーやドレナージインプラント手術のような外科的処置は、体液排出のための代替経路を作る最終手段です。これらの治療薬は、緑内障の重症度やタイプに応じて、単独または組み合わせて使用されます。
世界市場の主な原動力は、世界中で、特に老人人口の間で緑内障の有病率が増加していることです。これに伴い、早期発見のための診断技術の継続的な進歩が市場に弾みをつけています。さらに、新たなドラッグデリバリー方法の開発が、大きな成長促進要因として作用しています。これに加えて、製薬企業による研究開発への投資の増加が、市場に新たな活路を生み出しています。これに加え、定期的な眼科検診と緑内障症状の適時治療の重要性に対する意識の高まりが、これらの治療薬の採用を後押ししています。また、緑内障に関する知識を広めるための医療機関の取り組みも、市場にプラスの影響を与えています。これとは別に、専門の眼科医療センター数の増加が市場を促進しています。その他、ヘルスケアにアクセスできる中間所得層の拡大、個別化医療への注目の高まり、革新的な治療薬の登場なども市場に貢献しています。
外科手術における数々の技術革新
外科手術における技術革新の出現は、世界市場に大きな影響を与えています。最も画期的な開発の1つが低侵襲緑内障手術(MIGS)です。これらの外科的介入は、トラベクレクトミーのような伝統的な外科的方法よりも合併症が少なく、回復期間が短く、手術が容易であるため、変革的であることが証明されています。MIGSが容易に行えるようになったことで、外科医は患者の潜在的なリスクや不快感を最小限に抑えながら、病気を効果的に管理する選択肢が増えました。さらに、マイクロステントや新しいドレナージシステムなどの手術用医療機器の進歩は、緑内障手術の有効性をさらに向上させています。これらの進歩により、緑内障の実行可能な治療法としての外科的解決策に対する世界中のヘルスケア従事者や患者からの信頼が高まっています。
眼科における遠隔医療の採用増加
遠隔医療はヘルスケアの不可欠な一部となりつつあり、緑内障治療薬市場に関しては、眼科での応用が特に注目されています。ヘルスケアのデジタル化は、ソフトウェアやハードウェアの技術的進歩と相まって、遠隔診療を実用的かつ効果的なものにしています。患者は頻繁に病院を訪れることなく自分の状態をモニターできるようになり、これは特に地方や遠隔地に住む患者にとって有益です。このようにヘルスケア・サービスが広く行き渡ることで、患者のエンゲージメントが高まり、転帰の改善に貢献します。遠隔診療は継続的なモニタリングを可能にし、リアルタイム・データは、即時の介入が必要な患者の状態の変化をヘルスケア・プロバイダーに警告することができます。また、データ収集能力の向上は、これまでにない研究機会を提供し、新たな治療法の開発を加速させる可能性があります。
患者ケアへの全人的アプローチへの重点化
統合されたホリスティックな治療計画には、多くの場合、栄養士、理学療法士、心理カウンセラーなどを含むヘルスケア提供者の集学的チームが関与します。これにより、患者により包括的な治療計画が提供されるだけでなく、ヘルスケア・エコシステム内でのクロスセリングやアップセリングの機会も広がります。焦点は症状の治療から、より統合的なアプローチへと移っており、医学的介入と並行して、患者教育、生活習慣の改善、予防措置を考慮に入れています。ホリスティックなアプローチでは、緑内障の管理における食事、運動、ストレス管理などのライフスタイル要因の役割も認識されます。患者には、緑内障の重要な要因である眼圧を下げるのに役立つ食べ物や活動の種類についての教育が行われます。このような多方面からのアプローチは、医学的治療の効果を高めるだけでなく、患者の全体的な生活の質を向上させます。
IMARC Groupは、世界の緑内障治療薬市場レポートの各セグメントにおける主要動向の分析と、2023年から2028年までの世界、地域、国別レベルでの予測を提供しています。薬剤クラス別、適応症別、エンドユーザー別に市場を分類しています。
The global glaucoma therapeutics market size reached US$ 7.4 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 10.8 Billion by 2028, exhibiting a growth rate (CAGR) of 6.5% during 2022-2028. The growing prevalence of glaucoma across the globe, continual advancements in diagnostic technologies for early detection, the rising adoption of telemedicine in ophthalmology, and numerous technological innovations in surgical procedures represent some of the factors that are propelling the market.
Glaucoma is a group of eye conditions resulting in optic nerve damage, which can lead to vision loss. Typically managed through medications, laser treatment, or surgery, these interventions aim to reduce intraocular pressure (IOP), which is a key factor in glaucoma progression. Glaucoma therapeutics typically include medications such as prostaglandins, beta-blockers, and alpha agonists are commonly administered in eye drop form, targeting the reduction of eye fluid production or its improved outflow. Laser treatment, such as trabeculoplasty, is another method where laser beams focus on the eye's drainage system to facilitate fluid exit. Surgical procedures like trabeculectomy and drainage implant surgery are the final resorts to create alternative channels for fluid drainage. These therapeutics are used either in isolation or in combinations depending on the severity and type of glaucoma.
The global market is primarily driven by the growing prevalence of glaucoma across the globe, particularly among the geriatric population. In line with this, continual advancements in diagnostic technologies for early detection are providing an impetus to the market. Moreover, the development of new drug delivery methods is acting as a significant growth-inducing factor. In addition to this, increased investment in research and development by pharmaceutical companies is creating new avenues in the market. Besides this, the rising awareness about the importance of regular eye check-ups and timely treatment of glaucoma symptoms is encouraging the adoption of these therapeutics. Also, initiatives by health organizations to disseminate knowledge about glaucoma are positively impacting the market. Apart from this, growth in the number of specialized eye care centers is propelling the market. Some of the other factors contributing to the market include an expanding middle-class population with access to healthcare, a growing focus on personalized medicine, and the introduction of innovative therapeutic products.
Numerous technological innovation in surgical procedures
The advent of technological innovation in surgical procedures has significantly influenced the global market. One of the most groundbreaking developments is Minimally Invasive Glaucoma Surgeries (MIGS). These surgical interventions have proved to be transformative by causing fewer complications, necessitating shorter recovery periods, and being easier to perform than traditional surgical methods like trabeculectomy. The ease of MIGS has empowered surgeons with more options to manage the disease effectively while minimizing the potential risks and discomfort to the patient. In addition, advancements in surgical medical devices such as micro-stents and new drainage systems have further improved the effectiveness of glaucoma surgeries. These advancements have, in turn, increased the trust among healthcare practitioners and patients across the globe in surgical solutions as viable treatment options for glaucoma.
Rising adoption of telemedicine in ophthalmology
Telemedicine has increasingly become an integral part of healthcare, and its applications in ophthalmology are particularly noteworthy when it comes to the glaucoma therapeutics market. The digitalization of healthcare, coupled with technological advancements in software and hardware, has made remote consultations both practical and effective. Patients can now have their conditions monitored without the need for frequent hospital visits, which is especially beneficial for those residing in rural or remote locations. This wider reach of healthcare services enhances patient engagement, thereby contributing to better outcomes. Remote consultations enable continuous monitoring, and real-time data can alert healthcare providers to changes in a patient's condition that may require immediate intervention. The enhanced data collection capabilities also offer unprecedented opportunities for research, thereby potentially accelerating the development of new treatment modalities.
An enhanced focus on holistic approaches to patient care
An integrated, holistic treatment plan often involves a multi-disciplinary team of healthcare providers, including nutritionists, physiotherapists, and psychological counselors, among others. This not only gives patients a more comprehensive treatment plan but also opens up cross-selling and up-selling opportunities within the healthcare ecosystem. The focus has moved beyond treating the symptoms to a more integrated approach, taking into account patient education, lifestyle changes, and preventive measures alongside medical interventions. A holistic approach also recognizes the role of lifestyle factors such as diet, exercise, and stress management in managing glaucoma. Patients are educated about the types of foods and activities that can help in reducing intraocular pressure, which is a critical factor in glaucoma. This multi-pronged approach not only enhances the effectiveness of medical treatments but also improves the overall quality of life for the patients.
IMARC Group provides an analysis of the key trends in each segment of the global glaucoma therapeutics market report, along with forecasts at the global, regional, and country levels for 2023-2028. Our report has categorized the market based on drug class, indication and end user.
Prostaglandin Analogs
Beta Blockers
Alpha Adrenergic Agonists
Carbonic Anhydrase Inhibitors
Combination Drugs
Others
Prostaglandin analogs represents the largest market segment
The report has provided a detailed breakup and analysis of the market based on the drug class. This includes prostaglandin analogs, beta blockers, alpha adrenergic agonists, carbonic anhydrase inhibitors, combination drugs and others. According to the report, prostaglandin analogs represented the largest segment.
The prostaglandin analogs segment in the market is predominantly driven by their efficacy in reducing intraocular pressure with fewer systemic side effects compared to other classes of glaucoma medications. The once-daily dosing convenience of these drugs also contributes to patient compliance, thereby increasing its market demand. Innovation in formulations and delivery mechanisms is another major factor contributing to its market share. Intellectual property expiry and subsequent entry of generics, however, pose a challenge to market growth. Lastly, their versatile compatibility with other classes of glaucoma medications makes them a preferred choice in combination therapies, bolstering the segment's prominence.
On the other hand, the beta blockers, alpha adrenergic agonists, carbonic anhydrase inhibitors, combination drugs and other segments are influenced by a diverse range of factors such as affordability, varied mechanisms of action, and well-established safety profiles. These drugs are often prescribed in cases where Prostaglandin Analogs are contraindicated or not effective. Despite their efficacy, the need for multiple daily dosing can impact patient compliance. Availability of generics in this category also makes it a cost-effective option for treatment.
Open Angle Glaucoma
Angle Closure Glaucoma
Others
Open angle glaucoma represents the largest market segment
The report has provided a detailed breakup and analysis of the market based on the indication. This includes open angle glaucoma, angle closure glaucoma and others. According to the report, open angle glaucoma represented the largest segment.
The open-angle glaucoma segment is primarily fueled by its prevalence, constituting the majority of glaucoma cases globally. Increased awareness and advancements in diagnostic techniques have led to earlier and more frequent detection of this condition. The availability of multiple treatment options, ranging from medications to surgeries, offers a comprehensive approach to managing open-angle glaucoma. Aging demographics further amplify the incidence rates, thereby driving demand for therapeutic products. Government initiatives aimed at eye health contribute to the overall market growth for this segment.
On the other hand, the growth in angle closure glaucoma and other segments is primarily driven by an aging population, as the condition is more prevalent among older adults. Advances in diagnostic technologies have also contributed to the segment's expansion by enabling earlier and more accurate detection of the condition. In addition, the increased awareness about the severity of untreated angle-closure glaucoma, which can lead to blindness, has led to higher demand for effective treatments.
Hospitals
Ophthalmic Clinics
Ambulatory Surgery Centers
Others
Hospitals accounts for the majority of the market share
The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals, ophthalmic clinics, ambulatory surgery centers and others. According to the report, hospitals represented the largest segment.
Hospitals are major consumers in the glaucoma therapeutics market, given their capability to offer advanced diagnostic and surgical interventions. The consolidation of healthcare facilities and investment in state-of-the-art ophthalmic departments contribute to the segment's growth. Additionally, hospitals are often the first point of contact for emergency eye conditions, thereby positioning them as crucial stakeholders. Public and private insurance coverages also incentivize treatment in hospital settings, increasing patient throughput and consumption of glaucoma medications.
On the other hand, the growth in ophthalmic clinics, ambulatory surgery centers, and other segments can be attributed to the specialized focus on eye care, the availability of advanced diagnostic equipment, and faster patient turnover. Increasing consumer preference for specialized care is also a contributing factor. Decentralization of healthcare services and the expansion of ambulatory surgery centers make these settings accessible for minor procedures and regular check-ups. The growth is further supported by flexible payment options and shorter waiting times.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America exhibits a clear dominance, accounting for the largest glaucoma therapeutics market share
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.
The market in the North America region is significantly impelled by high healthcare expenditure, robust insurance frameworks, and the presence of leading pharmaceutical companies are primary drivers. Furthermore, the region is home to a diverse and aging population, thereby creating a natural demand for glaucoma treatments. Technological advancements in drug formulation and delivery, backed by substantial investments in research and development, also fuel market growth.
Regulatory support in terms of expedited approvals and grants fosters innovation, providing a favorable environment for market expansion. Government initiatives in healthcare education and eye screenings contribute to early diagnosis and, in turn, drive demand for therapeutics. Accessibility to specialty ophthalmic clinics and ambulatory surgery centers adds another layer of convenience, encouraging timely intervention.
The availability of both branded and generic drugs offers options across various price points, catering to a wide consumer base. Furthermore, collaborations between public and private sectors in healthcare initiatives serve to increase awareness as well as facilitate entry and acceptance of novel therapeutic solutions in the market.
The major players in the market are persistently working to develop more effective and less invasive treatment options. They are investing heavily in clinical trials to produce medicines and devices that provide longer-lasting relief with fewer side effects. Collaborations with research institutions and healthcare organizations are common strategies these key players are adopting. Market leaders are also expanding their portfolios by launching innovative products specifically designed to manage different types of glaucoma. Furthermore, these companies are working diligently to meet stringent regulatory requirements, ensuring that their products are both safe and effective. Furthermore, they are also focusing on patient education and awareness programs as a part of their market expansion strategies.
Aerie Pharmaceuticals Inc.
Allergan Plc
Bausch & Lomb Incorporated (Bausch Health Companies Inc.)
Inotek Pharmaceuticals Corp.
Merck & Co. Inc.
Novartis AG
Pfizer Inc.
Santen Pharmaceutical Co. Ltd.
SIFI S.p.A
Teva Pharmaceutical Industries Ltd
In November 2022, Aerie Pharmaceuticals, Inc. was acquired by Alcon, the global leader in eye care. Through the transaction, Alcon has added the commercial products Rocklatan(netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% and Rhopressa(netarsudil ophthalmic solution) 0.02%, AR-15512, a Phase 3 product candidate for dry eye disease and also a pipeline of ophthalmic pharmaceutical product candidates.
In July 2023, Bausch Health Companies Inc. announced that Bausch Receivables Funding LP, an Ontario limited partnership and wholly-owned subsidiary of Bausch Health, has entered into a $600 million non-recourse financing facility with KKR and its credit funds and accounts. The facility will be collateralized by certain accounts receivables originated by a wholly-owned subsidiary of Bausch Health.
Merck & Co. announced that the European Commission (EC) has approved KEYTRUDA, Merck's anti-PD-1 therapy, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma in adults whose tumors express PD-L1 (Combined Positive Score [CPS] ≥1).